Management of Symptomatic Advanced Pancreatic Adenocarcinoma

Pancreas Clinical Trial

Official title: Management of Symptomatic Advanced Pancreatic Adenocarcinoma: "Urgence Pancreas" - A Prospective A.R.CA.D Cohort Study

Status Recruiting

Clinical Trial Summary

This study assessed the feasibility and effects of an early integrative supportive care program in patient with Advanced pancreatic adenocarcinoma (aPDAC).

Clinical Trial Description

Two-step cohort study:

• Step 1 : A 14-day integrative supportive care program initiated as early as the clinical suspicion of aPDAC.

According to the investigator's assessment of patient needs, this integrative supportive care program will include:

• management of pain

• nutritional support

• pathologic diagnosis (endoscopy guides or percutaneous biopsies or ascitis cytology)

• diagnostic computed imaging

• endoscopic stenting of the bile duct and/or duodenum

• Step 2 : Follow up after the integrative supportive care program. According to their Eastern Cooperative Oncology Group Performance Status(ECOG PS) and/or chemotherapy

• Group 1 : Patient becoming eligible for treatment with FOLFIRINOX or nab-paclitaxel + gemcitabine and / or clinical trial

• Group 2 :Patient at the end of the 14-day program (Step 1) remaining with either :

a - Persisting ECOG PS ≥ 2

b - Clinico-biological features that make them ineligible to receive the FOLFIRINOX or nab-paclitaxel + gemcitabine regimens

c - Patient ineligible to other therapeutic clinical trial ;

Related Conditions & MeSH terms

• Adenocarcinoma
• Management Supportive Care Program
• Pancreas

• NCT number: NCT02979483
• Study type: Interventional
• Source: GERCOR - Multidisciplinary Oncology Cooperative Group
• Contact: Benoît ROUSSEAU, MD
• Email: benoit.rousseau@aphp.fr
• Status: Recruiting
• Phase: N/A
• Start date: November 2016
• Completion date: October 2020